Data from Pharmawand - Curated by EPG Health - Date added 10 July 2019

Genentech, a member of the Roche Group announced new data for Hemlibra (emicizumab-kxwh) across multiple pivotal studies in people with hemophilia A with and without factor VIII inhibitors at the International Society on Thrombosis and Haemostasis (ISTH) 2019 Congress on July 6-10 in Melbourne, Australia.

In total, Genentech presented 21 abstracts from its hemophilia program, including five oral presentations. Further data from the four pivotal HAVEN clinical trials were presented, demonstrating the long-term safety, efficacy and quality of life benefit of Hemlibra in people with hemophilia A with and without factor VIII inhibitors. Genentech also presented the first interim analysis from the Phase IIIb STASEY study, reinforcing the safety profile of Hemlibra in adults and adolescents (aged 12 years or older) with hemophilia A with factor VIII inhibitors seen in the HAVEN 1 clinical trial.

Long-term efficacy, safety and quality of life data show sustained benefit of Hemlibra : Updated data from the pooled HAVEN studies (HAVEN 1, HAVEN 2, HAVEN 3 and HAVEN 4; n=400), in people with hemophilia A of all ages with and without factor VIII inhibitors, showed that a high proportion of patients experienced zero treated bleeds on Hemlibra, and that this was maintained over a median of 83 weeks. Across all four HAVEN studies, over 87 percent of participants had no treated joint bleeds (either spontaneous or due to injury/trauma) and over 92 percent of participants experienced no spontaneous bleeds in each interval from week 25. Hemlibra’s established safety and tolerability profile was maintained. Additionally, updated data from the HAVEN 3 and HAVEN 4 studies demonstrate that Hemlibra prophylaxis offers a clinically meaningful improvement in long-term health-related quality of life, versus previous episodic or prophylactic factor VIII treatment, for people with hemophilia A with and without factor VIII inhibitors as measured by the Haem-A-QoL questionnaire. In the 28 days prior to starting treatment with Hemlibra, 76 percent and 79 percent of employed patients from HAVEN 3 and HAVEN 4 studies, respectively, reported no missed days of work. At week 25 of HAVEN 3 and HAVEN 4, 91 percent and 93 percent of participants reported no missed workdays, respectively, with these figures remaining stable thereafter.

Interim data from the STASEY study reinforce Hemlibra’s safety profile: Results from the first interim analysis of the Phase IIIb STASEY study, including data from 88 patients, reinforce the safety profile of Hemlibra characterized in the pivotal HAVEN 1 study. HAVEN 1 has formed the basis of Hemlibra’s approval in people with hemophilia A with factor VIII inhibitors in over 70 countries worldwide to date. In the STASEY study, in people with hemophilia A with factor VIII inhibitors, no cases of thrombotic microangiopathy or thrombotic events were reported and no new safety signals were identified. Eighteen (20.5 percent) patients reported a Hemlibra-related adverse event (AE), of which one was a serious AE (catheter site abscess). The most common AEs, occurring in 10 percent or more of people in the STASEY study were injection site reactions (14.8 percent), joint pain (arthralgia; 13.6 percent), headache (11.4 percent) and common cold symptoms (nasopharyngitis; 11.4 percent). Bleeding rates in people with hemophilia A with factor VIII inhibitors receiving Hemlibra in the STASEY study were also in line with previously reported observations from the HAVEN 1 study.

Additional factor treatment may not be needed for people on Hemlibra undergoing certain minor surgeries : A retrospective analysis of pooled data across the HAVEN studies suggests that people with hemophilia A with and without factor VIII inhibitors may not need additional preventative (prophylactic) coagulation factor (factor VIII replacement therapy or bypassing agents) when undergoing certain minor surgeries. The majority of minor surgeries (n=215) were performed without prophylactic coagulation factor (n=141; 65.6 percent), and of these, 90.8 percent did not result in a treated post-operative bleed. Of the 18 major surgeries, three were managed without prophylactic coagulation factor, with no post-operative bleeds. The remaining 15 major surgeries were managed with prophylactic coagulation factor, only one of which resulted in a treated post-operative bleed.

Comments

You will need to login, to leave a comment.

epgonline.org is not monitored for collection of adverse event reports. Any adverse events should be reported to your national reporting agency and/or the manufacturer.

Learning Zones

An epgonline.org Learning Zone (LZ) is an area of the site dedicated to providing detailed self-directed medical education about a disease, condition or procedure.

Oral Anticoagulation Reversal

Oral Anticoagulation Reversal

Experts discuss the use of non-vitamin K oral anticoagulants in the treatment and prevention of stroke, deep vein thrombosis and pulmonary embolism in atrial fibrillation patients.

Nephropathic Cystinosis

Nephropathic Cystinosis

Learn about the use of cystine-depleting pharmacotherapy and other supportive care measures for patients with nephropathic cystinosis.

+ 2 more

Chronic Lymphocytic Leukaemia (CLL)

Chronic Lymphocytic Leukaemia (CLL)

Refine your knowledge of chronic lymphocytic leukaemia (CLL) with information on pathophysiology, diagnosis, treatment options and more

+ 1 more

Load more

Related Content